Literature DB >> 17638129

S(+)-ibuprofen (dexibuprofen)--Excellent tolerance has not to be combined with poor clinical efficacy.

A Zohmann1, R Hawel, G Klein, W Kullich, G Lötsch.   

Abstract

S(+)-ibuprofen (dexibuprofen) is an NSAID offering a lot of advantages in the treatment of rheumatism and pain. A randomized double-blind, parallel group study in 110 patients showed equivalence in efficacy of 900 mg dexibuprofen (Seractil 300 mg, Gebro Fieberbrunn, Austria) vs. 150 mg diclofenac sodium. Regarding tolerance there was a trend to superiority of dexibuprofen. Therefore dexibuprofen can be characterized as an effective and very tolerable drug against inflammation and pain.

Entities:  

Year:  1998        PMID: 17638129     DOI: 10.1007/s10787-998-0008-2

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   5.093


  8 in total

Review 1.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Understanding the chiral pharmacology of nonsteroidal antiinflammatory drugs in the aryl propionic acid class: S(+) ibuprofen. Overview of the symposium "update on S(+) ibuprofen" (Going/Kitzbuehl, Austria, February 2-4, 1996)

Authors:  W J Wechter
Journal:  J Clin Pharmacol       Date:  1996-12       Impact factor: 3.126

3.  Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat.

Authors:  R Björkman; K M Hallman; J Hedner; T Hedner; M Henning
Journal:  J Clin Pharmacol       Date:  1996-12       Impact factor: 3.126

Review 4.  Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen.

Authors:  A M Evans
Journal:  J Clin Pharmacol       Date:  1996-12       Impact factor: 3.126

5.  Physical aspects of dexibuprofen and racemic ibuprofen.

Authors:  G Leising; R Resel; F Stelzer; S Tasch; A Lanziner; G Hantich
Journal:  J Clin Pharmacol       Date:  1996-12       Impact factor: 3.126

6.  [Double-blind comparative study of the effectiveness and tolerance of 900 mg dexibuprofen and 150 mg diclofenac sodium in patients with painful gonarthrosis].

Authors:  R Hawel; G Klein; J Mitterhuber; A Brugger
Journal:  Wien Klin Wochenschr       Date:  1997-01-31       Impact factor: 1.704

7.  [Determination of serum pepsinogen I and II for assessment of gastroduodenal tolerance of S(+) ibuprofen].

Authors:  W Kullich; H Wallner; G Klein
Journal:  Wien Klin Wochenschr       Date:  1994       Impact factor: 1.704

8.  Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium.

Authors:  J Hosie; M Distel; E Bluhmki
Journal:  Br J Rheumatol       Date:  1996-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.